DNLI
Price
$18.66
Change
-$0.02 (-0.11%)
Updated
Oct 22 closing price
Capitalization
2.98B
14 days until earnings call
Intraday BUY SELL Signals
KRYS
Price
$320.13
Change
-$2.04 (-0.63%)
Updated
Oct 22 closing price
Capitalization
9.48B
11 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs KRYS

DNLI vs KRYS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DNLI vs. KRYS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and KRYS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for DNLI with price predictions
Oct 22, 2026

DNLI's RSI Oscillator ascends from oversold territory

The RSI Indicator for DNLI moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 21 of the 24 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 70 cases where DNLI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for DNLI just turned positive on October 20, 2026. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.

Following a +7.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 209 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

DNLI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNLI as a result. In 77 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for DNLI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.571) is normal, around the industry mean (2.973). P/E Ratio (-6.570) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (2.300) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for KRYS with price predictions
Oct 22, 2026

KRYS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 16, 2026

KRYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 37 cases where KRYS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 54 cases where KRYS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in 260 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In 80 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 39 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.

KRYS moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KRYS crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

The Aroon Indicator for KRYS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.972) is normal, around the industry mean (2.973). P/E Ratio (38.710) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (438.009).

FUNDAMENTALS RATINGS
DNLI vs KRYS: Fundamental Ratings
DNLI
KRYS
OUTLOOK RATING
1..100
586
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
1009
SMR RATING
1..100
9846
PRICE GROWTH RATING
1..100
6142
P/E GROWTH RATING
1..100
2237
SEASONALITY SCORE
1..100
2250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (79) in the Biotechnology industry is in the same range as KRYS (92) in the Pharmaceuticals Major industry. This means that DNLI’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that KRYS’s stock grew significantly faster than DNLI’s over the last 12 months.

KRYS's SMR Rating (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for DNLI (98) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than DNLI’s over the last 12 months.

KRYS's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as DNLI (61) in the Biotechnology industry. This means that KRYS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (22) in the Biotechnology industry is in the same range as KRYS (37) in the Pharmaceuticals Major industry. This means that DNLI’s stock grew similarly to KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIKRYS
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
68%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
68%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
71%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
66%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (DNLI: $18.68 vs. KRYS: $322.17)
Brand notoriety: DNLI and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 78% vs. KRYS: 143%
Market capitalization -- DNLI: $2.98B vs. KRYS: $9.48B
DNLI [@Biotechnology] is valued at $2.98B. KRYS’s [@Biotechnology] market capitalization is $9.48B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 1 FA rating(s) are green while KRYS’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 1 green, 4 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while KRYS’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • KRYS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than KRYS.

Price Growth

DNLI (@Biotechnology) experienced а +4.53% price change this week, while KRYS (@Biotechnology) price change was -2.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

DNLI is expected to report earnings on Nov 05, 2026.

KRYS is expected to report earnings on Nov 02, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DNLI
Daily Signal:
Gain/Loss:
KRYS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with VIR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.11%
VIR - DNLI
52%
Loosely correlated
-1.32%
VCYT - DNLI
50%
Loosely correlated
-0.39%
EDIT - DNLI
48%
Loosely correlated
-0.80%
BEAM - DNLI
47%
Loosely correlated
-1.13%
SANA - DNLI
47%
Loosely correlated
+0.85%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-0.63%
VCYT - KRYS
44%
Loosely correlated
-0.39%
AXON - KRYS
43%
Loosely correlated
+2.98%
CADL - KRYS
41%
Loosely correlated
+0.12%
DNLI - KRYS
41%
Loosely correlated
-0.11%
REPL - KRYS
39%
Loosely correlated
+2.30%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPDV41.970.91
+2.22%
AAM S&P 500 High Dividend Value ETF (SPDV)
XFIV47.340.38
+0.81%
BondBloxx Bloomberg Five Year Target Duration US Treasury ETF (XFIV)
JFLX49.170.18
+0.37%
JPMorgan Flexible Debt ETF (JFLX)
JADE73.18-2.34
-3.09%
JPMorgan Active Developing Markets Equity ETF (JADE)
BPI25.11-0.84
-3.24%
Grayscale Bitcoin Premium Income ETF